Clinical Trial

Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
A Randomized, Placebo-Controlled Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2
Protocol Amendment History 44 amendments
This ClinicalTrials.gov record has been amended 44 times since 2020-11-12; most recent amendment 2026-07-01.
Status change: Active, Not Recruiting → Recruiting 2025-06-30
Status change: Recruiting → Active, Not Recruiting 2025-03-25
Status change: Not Yet Recruiting → Recruiting 2022-09-13
Trial Details
NCT Number NCT04628026
Lead Sponsor University of Ulm
Collaborators: Stichting Hemato-Oncologie voor Volwassenen Nederland
Conditions Acute Myeloid Leukemia
Enrollment 650 participants
Start Date 2022-09-13
Primary Completion 2029-03 (estimated)
Study Completion 2032-02 (estimated)
Updated on ClinicalTrials.gov 2026-08-06